theglobe_02

Criterium Logo Std Tag Line-2

www.CriteriumInc.com

MAY 2018    A Monthly Review of Articles of Interest for the Clinical Community

<This Month's Clinical Focus:  OPHTHALMOLOGY>

 

  ASCO 2018

MEET US AT ASCO ANNUAL 2018
JUNE 1-5  Chicago IL

CALL Ronny Schnel 310-619-6691
 


LumiThera Presents LIGHTSITE I Dry AMD Top Line Final Data


Topline final results now available from the LIGHTSITE I clinical trial for the treatment of dry age-related macular degeneration (AMD) utilizing its LT-300 Light Delivery System.

 

"LumiThera PBM treatment demonstrated reductions in central drusen volume over the course of the one-year study versus the sham treatment with statistical significance at one year, (p = 0.05).  Drusen is the hallmark pathology of dry AMD and is an important proinflammatory mediator and marker for disease progression," says Dr. Marion Munk, MD, PhD, a member of  the investigator team.
 

LumaThera LT-300-LED Prototype

"Results from the LIGHTSITE I study following treatment with a multi-wavelength PBM treatment demonstrated clinical improvements in vision outcome measures providing a strong foundation for initial therapy as well as the need for follow-up maintenance therapy," stated Samuel Markowitz, M.D., Co-Principal Investigator, Department of Ophthalmology and Vision Sciences, University of Toronto.  "The PBM therapy was most beneficial in dry AMD patients immediately following the completion of the treatment sessions. Contrast sensitivity or detailed vision was significantly improved throughout the year. Retreatments at a 6 month interval were performed to maintain clinical benefits."
 

"We are excited by the completion of the LIGHTSITE I trial and seeing the benefits in both clinical outcomes and drusen pathology," stated Clark Tedford, Ph.D., LumiThera President and CEO. "The LT-300 Light Delivery System performance was excellent throughout the clinical trial and patients provided positive feedback from their PBM treatment experience over the course of a year. This foundational data will accelerate our learning to develop options to treat complicated degenerative eye disease, where patient options are limited. The results demonstrate that the therapy is both a safe and effective treatment for early stage dry AMD patients. The current trial results will be used to refine the upcoming multi-center clinical trials expected to start initially in Europe."
 

"LumiThera's LIGHTSITE I data is the first prospective, sham controlled, double-masked, pilot clinical dry AMD study with PBM," says Dr. Robert Devenyi, Co-Principal Investigator, Ophthalmologist-in-Chief and Director of Retinal Services, UHN, University of Toronto. "The results show PBM using the LT-300 device can improve Visual Acuity and Contrast Sensitivity as vision endpoints for dry AMD patients to counteract the degradation in vision that this disabling disease brings."
 

The 30-subject pilot study was partially funded from a Small Business Innovation Research (SBIR) grant awarded to the Company from the National Institute of Health and the National Eye Institute.  The trial tested each subject's vision and examined disease pathology in the eye, following PBM treatments for up to one year.
 

The LT-300 is not yet approved for use by the Food & Drug Administration (FDA) in the USA. The device has not yet been granted a CE Mark by a Notified Body for commercial use outside of the USA. Visit the Company's website at www.lumithera.com.


SOURCE: Article usage courtesy of PRNewswire
 


UPDATE: Leber's Hereditary Optic Neuropathy (LHON)

 

GenSight Biologics reported 2.5 years of follow-up data from its phase I/II clinical trial of GS010 in patients with Leber Hereditary Optic Neuropathy (LHON).

Blurred Eye Chart courtesy of shutterstock_10621201 Paid Lic

These results confirm longterm sustained gains in visual acuity 2.5 years after a single intravitreal injection of GS010, especially in subjects with less than two years of onset of vision loss. In the study, five cohorts of three subjects were administered an increasing dose of GS010 via a single intravitreal injection in the eye more severely affected by the disease. Recruitment of 15 subjects was completed in April 2015 and long-term follow-up is ongoing.
 

Subjects had an average onset of vision loss of six years at the time of treatment. At baseline, both treated (TE) and untreated (UTE) eyes had an off-chart median visual acuity. At year 2.5 post-injection, in subjects less than two years from onset of vision loss and with relatively better vision at the time of treatment (<2.79 LogMAR), TE had a mean gain of +28 ETDRS letters (0.55 LogMAR) compared to baseline, while UTE had a mean gain of +13 ETDRS letters ( 0.25 LogMAR) compared to baseline.
 

The difference of +15 ETDRS letters in favor of TE is clinically significant, and the magnitude of the improvement, which is similar to the trend observed at weeks 48, 78, and 96, suggests sustained benefit from GS010. The subject group (n=5) with an onset of vision loss of less than two years and relatively better vision at the time of injection (<2.79 LogMAR) demonstrated a sustained pharmacological trend in favor of the treated eye, of increasing magnitude from week 36 onward, with 60% of subjects showing a clinically significant gain of = 15 letters in TE at year 2.5. At year 2.5 post-injection, GS010 continued to demonstrate a favorable tolerability profile, with no reports of worsening vision or ocular sequelae, serious treatment-emergent adverse events (TEAEs), nor systemic adverse events (AEs) related to GS010 or its administration.
 

GenSight Biologics is currently conducting two phase III clinical studies (RESCUE and REVERSE) in Europe and the U.S. to assess the efficacy of GS010 in subjects affected with LHON due to the ND4 mutation, and with vision loss up to one year at the time of treatment.


SOURCE: Article usage courtesy of CenterWatch


Image credits: LT-300-LED Device courtesy of LumaThera; Eyechart courtesy of Christophe Testi via Shutterstock Paid License

WHAT'S NEW AT CRITERIUM:
Current Global Studies
Ph II ORTHO - Knee Lesions
Ph II Pancreatic Cancer
Ph I/II Surgical Site Infections
Ph II Colorectal Cancer
Ph II Metastatic Breast Cancer
Ph II NSCLC
Ph I/II Myeloma (Amyloidosis)


SEE OUR STUDIES

CRITERIUM, Inc. Global CRO

Since 1991 Banner

OUR RESEARCH LIBRARY...
...is your access to continuing current information on successful clinical trials


FOLLOW OUR POSTS

See ALL POSTS at our BLOG

CRISPR Used to Restore Retinal Function

Orphan Drug Designation Granted for ALS

Beneficial Skin Bacteria Prevent Cancer

Huntington's Disease Kills Cancers

ALL USA Cancer Deaths Decline Again

 

WATCH OUR VIDEOS

Airport Network - One Minute with Criterium CRO on Excellence in Clinical Trials
Featured at Travellers Hubs in US Airports


The Clinical Data Liaison: The Key to Better, Faster Clinical Trials
Featuring John M. Hudak, Prersident & Founder


LISTEN to OUR PODCASTS

 CNN Interview with John Hudak 
Featured at
Travellers Hubs in US Airports

Criterium Celebrates 20 Years
Featuring John M. Hudak, President & Founder

The Site-Centric CRO: Best Practices for Excellent Site Relationships 
Featuring Ed Jahn, Clinical Ops Specialist & Jaime Hudak, CDL

The Clinical Data Liaison: Better, Faster Trials
Featuring John M. Hudak, President & Founder

Agile Clinical Trials and Real-Time Data
Featuring John M. Hudak, President & Founder


READ OUR PUBLICATIONS

The Evolution of the Data Management Role: The Clinical Data Liaison   Mary Stefanzick

Critical Clinical Research Factors in the Down Economy  Lawrence Reiter, Ph.D

No Longer Lost In Translation
Dr. Gavin Leong in PharmaVOICE Magazine

Maintaining Clinical Operations: It's Just Good Business  PharmaVoice View on Clinical Operations


EDC Implementation 
Greg Bailey in PharmaVOICE, View on E-Solutions

Going Global 
John M. Hudak in Future Pharmaceuticals

Trials Limber Up 
John M. Hudak in Int'l Clinical Trials Magazine


VIEW OUR PRESENTATION

Criterium Capabilities Presentation
Corporate Overview, Trials & Experience


DOWNLOAD OUR BROCHURE

Criterium:  Connect - Communicate - Control
Understand How We Do What We Do



MORE OPPORTUNITIES:


MAGI Conf Logo

MEET US AT:
MAGI’s
Clinical Research Conf East

MAY 20-23 Arlington VA

Call Ronny Schnel 310-619-6691



~ FOUNDED in 1991 ~
MANAGING SUCCESSFUL
Clinical Trials for over 25 years!

Resources are precious, time is the enemy, and results are paramount.

ACCELERATE
your clinical trials...
---------------------

CHANGE
the workflow paradigm...

- Information Management done right
- User-friendly technologies 
- Improved trial efficiencies
- Talented, committed in-house staff

Proprietary technology solutions 
PROVEN to improve your 
clinical trial results.


- MAXIMUM client outcomes
- Small and AGILE Global CRO
- WIDE RANGE of Indications
- Expanded Oncology Consortia

 

Contact: John Hudak, President at jmhudak@criteriuminc.com


 

 

 

 

 

 

 

 

 

 

 

 

 

GET TO KNOW US!

CONTACT US for an RFP or COMPETITIVE BID on your next project! 

FULL-SERVICE RESEARCH - TRIAL RESCUE SERVICES - PROJECT & DATA MANAGEMENT - BIOSTATISTICS
SITE SELECTION & MANAGEMENT - PROTOCOL DESIGN & CONSULTING - CLINICAL & MEDICAL MONITORING
CRF DESIGN - IxR & EDC - MEDICAL WRITING - SAFETY - REGULATORY CONSULTING - AND MORE!

About Criterium Inc.  Criterium Inc. www.criteriuminc.com is a global, full-service, technology-driven contract research organization that offers a unique mix of high-quality, innovative clinical research solutions for the biopharmaceutical, pharmaceutical, medical device, and CRO industries.